SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Walkingshadow who wrote (317)6/15/1999 11:45:00 PM
From: scaram(o)uche  Read Replies (2) of 3044
 
Is this how the release read??.......

"The company is pursuing a strategy to develop the most comprehensive obesity research program in the world to address this
important, unmet medical need. This effort is based on Millennium's preeminent six-year obesity and metabolic disease program
that has successfully identified over a dozen genes involved in weight regulation, all of which are common to a single metabolic pathway"

No? Shucks.

Yes, I suppose that it's likely that MLNM will derive royalties from Roche.

>> if you don't know the answer to my question, a
simple "I don't know" or no response would suffice. <<

When and if that day rolls around, I'll certainly choose that route. Do us a favor and pop back into the BGEN thread (that's BGEN for Biogen) and flesh out that CRF post, would you please? Are you hottest for endothelin A receptor antagonists? What are those existing therapies that you think so highly of?

Thanks.

Rick

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News